Elisabeth F. Beaber

Elisabeth F. Beaber

Auto-generated profile, based on publicly available information

Elisabeth F. Beaber

Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington (E.F.B., Y.Z.)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2022 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
EBElisabeth F. Beaber
Elisabeth F. Beaber
AKAruna Kamineni
Aruna Kamineni
ABAndrea N. Burnett-Hartman
Andrea N. Burnett-Hartman
BHBrian Hixon
Brian Hixon
SKSarah C. Kobrin
Sarah C. Kobrin
VDV. Paul Doria-Rose
V. Paul Doria-Rose
Background: Cancer screening is a complex process involving multiple steps and levels of influence (e.g., patient, provider, facility, health care system, community, or neighborhood). We describe the design, methods, and research agenda of the Population-based Research to Optimize the Screening Process (PROSPR II) consortium. PROSPR II Research Centers (PRC), and the Coordinating Center aim to identify opportunities to improve screening processes and reduce disparities through investigation of factors affecting cervical, colorectal, and lung cancer screening in U.S. community health care settings. Methods: We collected multilevel, longitudinal cervical, colorectal, and lung cancer screening process data from clinical and administrative sources on >9 million racially and ethnically diverse individuals across 10 heterogeneous health care systems with cohorts beginning January 1, 2010. To facilitate comparisons across organ types and highlight data breadth, we calculated frequencies of multilevel characteristics and volumes of screening and diagnostic tests/procedures and abnormalities. Results: Variations in patient, provider, and facility characteristics reflected the PROSPR II health care systems and differing target populations. PRCs identified incident diagnoses of invasive cancers, in situ cancers, and precancers (invasive: 372 cervical, 24,131 colorectal, 11,205 lung; in situ: 911 colorectal, 32 lung; precancers: 13,838 cervical, 554,499 colorectal). Conclusions: PROSPR II's research agenda aims to advance: (i) conceptualization and measurement of the cancer screening process, its multilevel factors, and quality; (ii) knowledge of cancer disparities; and (iii) evaluation of the COVID-19 pandemic's initial impacts on cancer screening. We invite researchers to collaborate with PROSPR II investigators. Impact: PROSPR II is a valuable data resource for cancer screening researchers.

1 November 2022 in Annals of Internal Medicine
Verified
Journal Article
Open access
AKAruna Kamineni
Aruna Kamineni
VDV. Paul Doria-Rose
V. Paul Doria-Rose
JCJessica Chubak
Jessica Chubak
JIJohn M. Inadomi
John M. Inadomi
DCDouglas A. Corley
Douglas A. Corley
ABAndrea N. Burnett-Hartman
Andrea N. Burnett-Hartman
Screening guidelines should consider both benefits and harms of screening. The authors reviewed screening guidelines in 5 organ systems (breast, cervical, colorectal, lung, and prostate), and they ... Background: Cancer screening should be recommended only when the balance between benefits and harms is favorable. This review evaluated how U.S. cancer screening guidelines reported harms, within a...

15 September 2022 in Cancer Medicine
Verified
Journal Article
Open access
CCChun R. Chao
Chun R. Chao
JCJessica Chubak
Jessica Chubak
EBElisabeth F. Beaber
Elisabeth F. Beaber
AKAruna Kamineni
Aruna Kamineni
CMConnie Mao
Connie Mao
CWCosette M. Wheeler
Cosette M. Wheeler
Background: Potential care gaps in the cervical cancer screening process among women diagnosed with cervical cancer in an era with increased human papillomavirus (HPV) testing have not been extensively evaluated.Methods: Women diagnosed with cervical cancer between ages 21 and 65 at four study sites between 2010 and 2014 were included. Screening histories were ascertained from 0.5 to 4 years prior to cervical cancer diagnosis. We identified potential care gaps in the screening history for each woman and classified them into one of three mutually exclusive types: lack of a screening test, screening test failure, and diagnostic/treatment care gap. Distributions of care gaps were tabulated by stage, histology, and study site. Multivariable nominal logistic regression was used to examine the associations between demographic and cancer characteristics and type of care gap.Results: Of 499 women evaluated, 46% lacked a screening test in the time window examined, 31% experienced a screening test failure, and 22% experienced a diagnostic/treatment care gap. More than half of the women with advanced cancer and squamous cell carcinoma lacked a screening test compared to 31% and 24% of women with localized cancer and adenocarcinoma, respectively. Women aged 21–29 at diagnosis were more likely to experience screening test failure and diagnostic/treatment care gap, while those aged 50–65 were more likely to lack a screening test, compared to women aged 30–39.Conclusions: Our findings demonstrate a continuing need to develop interventions targeting unscreened and under‐screened women and improve detection and diagnosis of adenocarcinoma in women undergoing cervical cancer screening and diagnostic follow‐up.

26 November 2025
Verified
Other
Open access
EBElisabeth F. Beaber
Elisabeth F. Beaber
AKAruna Kamineni
Aruna Kamineni
ABAndrea N. Burnett-Hartman
Andrea N. Burnett-Hartman
BHBrian Hixon
Brian Hixon
SKSarah C. Kobrin
Sarah C. Kobrin
VDV. Paul Doria-Rose
V. Paul Doria-Rose
Supplementary Table from Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda

26 November 2025
Verified
Other
Open access
EBElisabeth F. Beaber
Elisabeth F. Beaber
AKAruna Kamineni
Aruna Kamineni
ABAndrea N. Burnett-Hartman
Andrea N. Burnett-Hartman
BHBrian Hixon
Brian Hixon
SKSarah C. Kobrin
Sarah C. Kobrin
VDV. Paul Doria-Rose
V. Paul Doria-Rose
Supplementary Table from Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda

26 November 2025
Verified
Other
Open access
EBElisabeth F. Beaber
Elisabeth F. Beaber
AKAruna Kamineni
Aruna Kamineni
ABAndrea N. Burnett-Hartman
Andrea N. Burnett-Hartman
BHBrian Hixon
Brian Hixon
SKSarah C. Kobrin
Sarah C. Kobrin
VDV. Paul Doria-Rose
V. Paul Doria-Rose
Supplementary Table from Evaluating and Improving Cancer Screening Process Quality in a Multilevel Context: The PROSPR II Consortium Design and Research Agenda